NCT00299325 - VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt | Biotech Hunter

Enrollment

254

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions

Metabolic Syndrome

Interventions

DRUG

Rimonabant

Tablet, oral administration

DRUG

Placebo (for Rimonabant)

Tablet, oral administration

OTHER

Mild hypocaloric diet

Calculated by the dietitian based on the estimated basal metabolism rate and the physical activity

Trial Locations (9)

Sanofi-Aventis Administrative Office, Bridgewater

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Hoersholm

Sanofi-Aventis Administrative Office, Helsinki

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, Barcelona

Sanofi-Aventis Administrative Office, Stockholm

Sanofi-Aventis Administrative Office, Guildford